Brii Biosciences (HKG:2137) posted a loss attributable to owners of 222.6 million yuan for 2025, narrowing from 508.2 million yuan a year earlier, according to a Thursday Hong Kong bourse filing.
Shares of the drug company were down over 6% in Friday morning trade.
Loss per share came in at 0.31 yuan, compared with a loss of 0.70 yuan a year earlier.
Revenue was 18.6 million yuan from nil in 2024.